30. Rugo HR, Roche H, Thomas E et al. Ixabepilone-capecitabine vs Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer Patients and methods: Preoperative CA 15-3 and CEA levels of 1681 patients were measured. The association of both tumor markers levels with clinicopathological parameters and outcomes was investigated by univariate and multivariate analyses.
introduction
Breast cancer is the most frequently occurring cancer in women from western countries and continues to be the most common fatal cancer together with lung, bronchus and colorectum cancers [1] . It is also the second most common malignancy in Korean women [2] . Despite the rising incidence of breast cancer, the survival rates have improved in recent years due to earlier detection and an increasing use of more effective systemic treatments based on prognostic factors [3] .
Therefore, identifying prognostic and predictive factors is important to assist in decision making about treatment and to improve survival.
Along with the traditional prognostic factors such as tumor size, tumor grade, and lymph node status [4] , the prognostic value of serum tumor markers has been investigated in breast cancer [5] [6] [7] [8] . Some studies suggested that elevated carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) levels provided the significant prognostic information; however, others reported no independent value of serum tumor markers [5] [6] [7] . Recently, Maric et al. [8] reviewed the role of serum tumor markers in breast cancer and they pointed out conflicting results of its prognostic value and rather emphasized the necessity of more extensive investigations for improved and a more cost-effective management of breast cancer. The American Society of Clinical Oncology (ASCO) guidelines do not currently recommend the use of serum CA 15-3 and CEA for breast cancer screening, as a routine surveillance tool or for therapeutic response monitoring due to inconsistent findings of their sensitivity and specificity [9] . However, serum tumor markers such as CA 15-3 and CEA are the most widely used serum tumor markers for surveillance purposes and treatment response in clinical practice [10] [11] [12] [13] .
Previously, we reported that patients with elevated preoperative levels of CA 15-3 and CEA had worse outcomes than those with normal levels by stage-matched and multivariate analyses [14] . However, our previous study had a relatively short follow-up duration and a small sample size. Therefore, we aimed to reconfirm the prognostic value of preoperative CA 15-3 and CEA levels while overcoming the previous limitations. We reinvestigated the data of our previous study cohort of 740 patients with extended follow-up and then added consecutively diagnosed breast cancer patients with a larger sample size.
patients and methods

patients selection
From April 1999 to December 2006, we investigated serum CA 15-3 and CEA concentration levels from a total of 1681 patients who were treated for stage I-III invasive breast cancer at Yonsei University Severance Hospital; 740 patients (group I) who had breast surgery between April 1999 and December 2003 [14] and another 941 patients (group II) who had breast surgery between January 2004 and December 2006. We excluded patients with stage IV disease at diagnosis, carcinoma in situ, unknown TNM stage and receiving neoadjuvant chemotherapy. All data including serum CA 15-3 and CEA levels at the time of diagnosis were obtained from the Severance Hospital Breast Cancer Registry, which is a prospectively maintained database that includes clinical and pathological information, treatment modality, and details of outcomes including disease recurrence and death. Retrospectively to confirm the significance of preoperative serum CA 15-3 and CEA levels in this longer follow-up study, we first reinvestigated the survival outcomes of group I and then evaluated the relationship between the level of tumor markers, clinicopathological characteristics and survival outcomes in a larger study population including groups I and II.
Management of all patients was based on international guidelines and adjuvant treatment with radiotherapy, chemotherapy and hormone therapy was not altered according to the marker levels. TNM staging was based on the sixth American Joint Committee on Cancer criteria. To detect local or distant relapse, clinical follow-up was carried out every 6 to 12 months, which included recording patient's history, physical examination, laboratory tests of CEA, CA 15-3, complete blood counts, and liver function test, chest radiography, mammography, breast and abdominopelvic ultrasonography, and bone scans. In addition, a computed tomography (CT) scan or a fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)/CT scan was carried out if necessary.
tumor marker analysis
We measured the concentration of serum tumor markers by using automated immunoanalyzer systems using a chemiluminescent . We defined the cut-off values of tumor marker as the 95th percentile of healthy individuals, which was already used in our previous study (CA 15-3: 20.11 U/L, CEA: 3.88 ng/ml) [14] . Tumors with ≥10% nuclear-stained cells were considered positive for the estrogen receptor (ER) and progesterone receptor (PR). Human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) was carried out using the HercepTest™ (DAKO, Glostrup, Denmark) and interpreted as 0, 1+, 2+, or 3+. HER2 was considered positive in cases with an IHC 3+ score.
statistical analysis
The difference between proportions was evaluated by the chi-square test. Disease-free survival (DFS) was defined to be from the time of surgery to the locoregional recurrence, distant metastasis, and death before recurrence. Distant relapse-free survival (DRFS) was defined as the time from surgery to the distant recurrence. Overall survival (OS) was defined to be from the time of surgery to death from any cause. DFS and OS were estimated using the Kaplan-Meier method and the group differences in survival time were tested using the log-rank test. Multivariate Cox's proportional hazard analysis was carried out to compare and identify independent prognostic factors for DFS, DRFS and OS and to calculate hazard ratios. All significant parameters in the univariate analysis were entered into a multivariate model. All reported P values are two-sided, and P values <0.05 were considered significant. SPSS for Windows (version 15.0) was used for all statistical analyses.
results
The median age of the study population was 48 years (range 20-88 years) and the median follow-up time was 72 months (range 0.8-143.6 months). The median follow-up duration was extended to 98.8 months for the previously reported group I patients and was 63.0 months for the newly added 941 patients (group II). The general characteristics of the study population are summarized in Table 1 . Compared with the group I patients, the group II patients were older, detected earlier, had favorable characteristics, and a few number of elevated preoperative tumor marker levels. During follow-up, among the total study population, recurrence occurred in 208 patients (first relapse: local recurrence alone n = 32, systemic recurrence alone n = 124, both local and systemic recurrences n = 52) and death occurred in 150 patients. Survival curves of group I with an extended follow-up duration are shown in Figure 1 . Elevated CA 15-3 or CEA levels were clearly associated with poor DFS and OS, respectively ( Figure 1A , B, D, and E). Patients with normal levels of both CA 15-3 and CEA showed better DFS and OS than those with elevated either one or both markers levels (P < 0.001). Elevation of either one marker level was associated with significantly better DFS (P = 0.022) and an improved trend of OS (P = 0.08) than elevation of both markers ( Figure 1C and F) . Using the longer follow-up in this study, the statistical significance was reaffirmed from the previous study [14] .
Elevated CA 15-3 and CEA levels were identified in 176 (10.5%) and 131(7.8%) patients, respectively, among whole group I and II patients ( Table 1 ). The correlation between serum CA 15-3 and CEA levels and clinicopathological characteristics are shown in Table 2 . Similar to the previous study [14] , both CA 15-3 and CEA levels were correlated with 
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larger tumor size and advanced nodal stage, but not with ER nor PR expressions. Higher concentration of CA 15-3 was related to histologic grade III tumors and higher concentration of CEA was correlated with HER2 positivity in the current study. Since adjuvant treatment was not determined by tumor marker levels, there was no difference in adjuvant treatment according to CA 15-3 and CEA levels, but more patients with elevated CA15-3 levels received chemotherapy and this was not statistically significant (supplementary Table S1 , available at Annals of Oncology online).
In our study population of 1681 patients, elevated CA 15-3 and CEA levels were significantly associated with worse DFS and OS (Figure 2 ). In this longer follow-up and larger study population, the statistical significance was more intensified and the survival curves were distinctively different according to tumor markers. In tumor stage-matched analysis, patients with elevated CA 15-3 levels showed significantly worse DFS and OS in stages I (P = 0.042 and 0.002, respectively) and II (P < 0.001 and P = 0.034, respectively), but not in stage III (supplementary Figure S1 , available at Annals of Oncology online). By analysis of CEA levels, an elevated CEA group showed a significantly worse DFS and OS in all stages I-III (supplementary Figure S2 , available at Annals of Oncology online).
Multivariate analysis adjusting for the most important conventional prognostic factors revealed that elevated preoperative CA 15-3 and CEA levels were independent prognostic factors in DFS, DRFS and OS. Traditional clinicopathological factors such as age, tumor size, node metastasis, and ER status also had independent prognostic power in the Cox's models (Table 3) . Both CA 15-3 and CEA levels were elevated in 28 patients, either CA 15-3 or CEA was elevated in 251 patients, and the remaining 1402 patients had normal ranges of both the markers. Patients with normal levels of both the markers showed the best DFS and OS. Subsequently, those with either one elevated marker level demonstrated better survival, and finally, those with both elevated markers presented the worst survival (both normal versus either elevated, P < 0.001 for DFS, and P < 0.001 for OS; and both normal versus both elevated, P < 0.001 for DFS, and P < 0.001 for OS) (Figure 3 ).
discussion
The prognostic value of preoperative serum tumor marker CA 15-3 and CEA was demonstrated in our previous study, which included 740 patients with a median follow-up of 37.2 months [14] . Our previous findings were reconfirmed and even solidified in the present study with an extended follow-up of 98.8 months (Figure 1) . Nine hundred and forty-one patients were added to the previous study population of 740, and the current analysis was carried out in a larger study population of 1681 with a median follow-up of 72 months.
With the activation of a national screening program, the proportion of screening-detection remarkably increased from 5.0% to 32.6% and the incidence of stage I breast cancer also increased from 19.6% to 34.8% between 1996 and 2008 in Korea [15] . As expected, the incidence of patients with elevated preoperative levels of serum CA 15-3 and CEA decreased along with the increase in early breast cancer patients in the current study (Table 1) . This finding supports the proposed association of tumor burden and elevated levels of serum tumor markers. The preoperative serum CEA and CA 15-3 levels are associated with the tumor size and lymph node metastasis which represents tumor burden [14, 16, 17] and significantly higher levels of CEA and CA 15-3 were seen in patients with advanced disease than in those with locoregional breast cancer [9, 13, 18] . The current study also demonstrated the association of higher levels of CA 15-3 and CEA with tumor burden such as larger tumor size, node metastases, and advanced stage in a large study population with longer followup. Although the association of tumor markers and tumor biological factors is not well established [19] , the serum CA 15-3 level was related to the poor histological grade in agreement with the recent study by Molina et al. [5, 20] . The relationship between higher levels of CEA and HER2 expression needs to be further investigated.
Since elevated levels of CA 15-3 and CEA are related to the tumor burden and higher levels may indicate vascularization of the tumor with an increased likelihood of occult systemic original articles Annals of Oncology metastases [21, 22] , elevated CA 15-3 and CEA concentration at initial presentation could be predictive of poor breast cancer outcome [23] . In agreement with other studies demonstrating significant association between the preoperative tumor marker levels and the survival outcome [14, 21, 24, 25] , the elevated preoperative CA 15-3 or CEA levels were significantly associated with poor DFS (P < 0.001 and P < 0.001, respectively) and OS (P < 0.001 and P < 0.001, respectively) ( Figure 2 ), even in a stage-matched analysis (supplementary Figures S1 and S2, available at Annals of Oncology online).
With a longer follow-up and a larger population of the present study, the prognostic significance of tumor marker elevation became more confident and extended to almost all stages. The prognostic significance was also maintained in the multivariate analysis with the addition of other traditional prognostic factors such as age, tumor size, lymph node metastasis, and ER status (Table 3) . Although the ASCO panel does not recommend therapeutic decisions be based on the serum tumor marker status [9] , several studies showed that the preoperative concentration of tumor markers could be useful in combination with other factors in deciding whether adjuvant chemotherapy should be administered [5, 13, 23, 26] . Furthermore, higher levels may reflect an increased likelihood of occult systemic metastases [21] and the study evaluating early treatment based on increasing tumor marker concentrations showed improved outcomes compared with controls [27] . Compared with the results of previous study [14] , the prognostic value of the combination of both marker levels was further intensified with a longer follow-up and with a larger study population. Patients with either one or both markers elevated showed significantly worse survival outcomes than those with both normal ranges of markers in the current study. Therefore, elevated preoperative serum tumor markers could be useful in discriminating high-risk groups and in deciding adjuvant systemic treatment, for which the hypothesis should be verified.
In conclusion, our previous findings of independent prognostic significance of elevated preoperative serum CA 15-3 and CEA levels [14] are reconfirmed with the extended followup and larger study population in the present analyses. Preoperative serum CA 15-3 and CEA levels can provide additional prognostic information and may be useful in treatment implementation. Therefore, both the markers could be considered for the risk evaluation and determination of adjuvant treatment strategies in clinical practice, although this hypothesis should be further validated. Further clinical trials based on the tumor marker levels are necessary.
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references Figure 3 . Disease-free survival (DFS) (A) and overall survival (OS) (B) according to the combination of both marker levels in group I and II patients. The bold line represents patients with normal levels of both markers, the dotted line represents patients with elevated either marker, and the chain line represents patients with both markers elevated.
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